Supplementary Tables – Biomarker subset analysis of a Phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC
datasetposted on 2022-02-04, 08:53 authored by Figshare Future Science GroupFigshare Future Science Group, Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu, Jie Wang
Supplementary Table 1. TRAEs occurring in ≥10% of patients.
Supplementary Table 2. Subgroup analysis of TTSP and PFS in biomarker group.